array(4) {
  ["posts_per_page"]=>
  string(1) "5"
  ["cat"]=>
  int(21)
  ["p"]=>
  string(0) ""
  ["suppress_filters"]=>
  int(0)
}
array(6) {
  ["posts_per_page"]=>
  string(1) "5"
  ["cat"]=>
  int(21)
  ["p"]=>
  string(0) ""
  ["suppress_filters"]=>
  int(0)
  ["paged"]=>
  int(3)
  ["meta_query"]=>
  array(1) {
    [0]=>
    array(0) {
    }
  }
}
object(WP_Query)#3378 (56) {
  ["query"]=>
  array(6) {
    ["posts_per_page"]=>
    string(1) "5"
    ["cat"]=>
    int(21)
    ["p"]=>
    string(0) ""
    ["suppress_filters"]=>
    int(0)
    ["paged"]=>
    int(3)
    ["meta_query"]=>
    array(1) {
      [0]=>
      array(0) {
      }
    }
  }
  ["query_vars"]=>
  array(62) {
    ["posts_per_page"]=>
    int(5)
    ["cat"]=>
    int(21)
    ["p"]=>
    int(0)
    ["suppress_filters"]=>
    int(0)
    ["paged"]=>
    int(3)
    ["meta_query"]=>
    array(1) {
      [0]=>
      array(0) {
      }
    }
    ["error"]=>
    string(0) ""
    ["m"]=>
    string(0) ""
    ["post_parent"]=>
    string(0) ""
    ["subpost"]=>
    string(0) ""
    ["subpost_id"]=>
    string(0) ""
    ["attachment"]=>
    string(0) ""
    ["attachment_id"]=>
    int(0)
    ["name"]=>
    string(0) ""
    ["static"]=>
    string(0) ""
    ["pagename"]=>
    string(0) ""
    ["page_id"]=>
    int(0)
    ["second"]=>
    string(0) ""
    ["minute"]=>
    string(0) ""
    ["hour"]=>
    string(0) ""
    ["day"]=>
    int(0)
    ["monthnum"]=>
    int(0)
    ["year"]=>
    int(0)
    ["w"]=>
    int(0)
    ["category_name"]=>
    string(12) "publications"
    ["tag"]=>
    string(0) ""
    ["tag_id"]=>
    string(0) ""
    ["author"]=>
    string(0) ""
    ["author_name"]=>
    string(0) ""
    ["feed"]=>
    string(0) ""
    ["tb"]=>
    string(0) ""
    ["comments_popup"]=>
    string(0) ""
    ["meta_key"]=>
    string(0) ""
    ["meta_value"]=>
    string(0) ""
    ["preview"]=>
    string(0) ""
    ["s"]=>
    string(0) ""
    ["sentence"]=>
    string(0) ""
    ["fields"]=>
    string(0) ""
    ["menu_order"]=>
    string(0) ""
    ["category__in"]=>
    array(0) {
    }
    ["category__not_in"]=>
    array(0) {
    }
    ["category__and"]=>
    array(0) {
    }
    ["post__in"]=>
    array(0) {
    }
    ["post__not_in"]=>
    array(0) {
    }
    ["tag__in"]=>
    array(0) {
    }
    ["tag__not_in"]=>
    array(0) {
    }
    ["tag__and"]=>
    array(0) {
    }
    ["tag_slug__in"]=>
    array(0) {
    }
    ["tag_slug__and"]=>
    array(0) {
    }
    ["post_parent__in"]=>
    array(0) {
    }
    ["post_parent__not_in"]=>
    array(0) {
    }
    ["author__in"]=>
    array(0) {
    }
    ["author__not_in"]=>
    array(0) {
    }
    ["ignore_sticky_posts"]=>
    bool(false)
    ["cache_results"]=>
    bool(true)
    ["update_post_term_cache"]=>
    bool(true)
    ["update_post_meta_cache"]=>
    bool(true)
    ["post_type"]=>
    string(0) ""
    ["nopaging"]=>
    bool(false)
    ["comments_per_page"]=>
    string(2) "50"
    ["no_found_rows"]=>
    bool(false)
    ["order"]=>
    string(4) "DESC"
  }
  ["tax_query"]=>
  object(WP_Tax_Query)#3399 (6) {
    ["queries"]=>
    array(1) {
      [0]=>
      array(5) {
        ["taxonomy"]=>
        string(8) "category"
        ["terms"]=>
        array(1) {
          [0]=>
          int(21)
        }
        ["field"]=>
        string(7) "term_id"
        ["operator"]=>
        string(2) "IN"
        ["include_children"]=>
        bool(true)
      }
    }
    ["relation"]=>
    string(3) "AND"
    ["table_aliases":protected]=>
    array(1) {
      [0]=>
      string(21) "wp_term_relationships"
    }
    ["queried_terms"]=>
    array(1) {
      ["category"]=>
      array(2) {
        ["terms"]=>
        array(1) {
          [0]=>
          int(21)
        }
        ["field"]=>
        string(7) "term_id"
      }
    }
    ["primary_table"]=>
    string(8) "wp_posts"
    ["primary_id_column"]=>
    string(2) "ID"
  }
  ["meta_query"]=>
  object(WP_Meta_Query)#3398 (9) {
    ["queries"]=>
    array(0) {
    }
    ["relation"]=>
    string(3) "AND"
    ["meta_table"]=>
    NULL
    ["meta_id_column"]=>
    NULL
    ["primary_table"]=>
    NULL
    ["primary_id_column"]=>
    NULL
    ["table_aliases":protected]=>
    array(0) {
    }
    ["clauses":protected]=>
    array(0) {
    }
    ["has_or_relation":protected]=>
    bool(false)
  }
  ["date_query"]=>
  bool(false)
  ["post_count"]=>
  int(5)
  ["current_post"]=>
  int(-1)
  ["in_the_loop"]=>
  bool(false)
  ["comment_count"]=>
  int(0)
  ["current_comment"]=>
  int(-1)
  ["found_posts"]=>
  string(2) "67"
  ["max_num_pages"]=>
  float(14)
  ["max_num_comment_pages"]=>
  int(0)
  ["is_single"]=>
  bool(false)
  ["is_preview"]=>
  bool(false)
  ["is_page"]=>
  bool(false)
  ["is_archive"]=>
  bool(true)
  ["is_date"]=>
  bool(false)
  ["is_year"]=>
  bool(false)
  ["is_month"]=>
  bool(false)
  ["is_day"]=>
  bool(false)
  ["is_time"]=>
  bool(false)
  ["is_author"]=>
  bool(false)
  ["is_category"]=>
  bool(true)
  ["is_tag"]=>
  bool(false)
  ["is_tax"]=>
  bool(false)
  ["is_search"]=>
  bool(false)
  ["is_feed"]=>
  bool(false)
  ["is_comment_feed"]=>
  bool(false)
  ["is_trackback"]=>
  bool(false)
  ["is_home"]=>
  bool(false)
  ["is_404"]=>
  bool(false)
  ["is_comments_popup"]=>
  bool(false)
  ["is_paged"]=>
  bool(true)
  ["is_admin"]=>
  bool(false)
  ["is_attachment"]=>
  bool(false)
  ["is_singular"]=>
  bool(false)
  ["is_robots"]=>
  bool(false)
  ["is_posts_page"]=>
  bool(false)
  ["is_post_type_archive"]=>
  bool(false)
  ["query_vars_hash":"WP_Query":private]=>
  string(32) "13afa6b800fa2cf41b35870c3677769d"
  ["query_vars_changed":"WP_Query":private]=>
  bool(false)
  ["thumbnails_cached"]=>
  bool(false)
  ["stopwords":"WP_Query":private]=>
  NULL
  ["compat_fields":"WP_Query":private]=>
  array(2) {
    [0]=>
    string(15) "query_vars_hash"
    [1]=>
    string(18) "query_vars_changed"
  }
  ["compat_methods":"WP_Query":private]=>
  array(2) {
    [0]=>
    string(16) "init_query_flags"
    [1]=>
    string(15) "parse_tax_query"
  }
  ["tribe_is_event"]=>
  bool(false)
  ["tribe_is_multi_posttype"]=>
  bool(false)
  ["tribe_is_event_category"]=>
  bool(false)
  ["tribe_is_event_venue"]=>
  bool(false)
  ["tribe_is_event_organizer"]=>
  bool(false)
  ["tribe_is_event_query"]=>
  bool(false)
  ["tribe_is_past"]=>
  bool(false)
  ["request"]=>
  string(920) "SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID FROM wp_posts  INNER JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) JOIN wp_icl_translations t
							ON wp_posts.ID = t.element_id
								AND t.element_type = CONCAT('post_', wp_posts.post_type)  WHERE 1=1  AND ( 
  wp_term_relationships.term_taxonomy_id IN (21)
) AND wp_posts.post_type = 'post' AND (wp_posts.post_status = 'publish' OR wp_posts.post_status = 'tribe-ea-success' OR wp_posts.post_status = 'tribe-ea-failed' OR wp_posts.post_status = 'tribe-ea-schedule' OR wp_posts.post_status = 'tribe-ea-pending' OR wp_posts.post_status = 'tribe-ea-draft') AND ( ( t.language_code = 'en' AND wp_posts.post_type  IN ('post','page','tribe_venue','tribe_organizer','tribe_events' )  ) OR wp_posts.post_type  NOT  IN ('post','page','tribe_venue','tribe_organizer','tribe_events' )  ) GROUP BY wp_posts.ID ORDER BY wp_posts.post_date DESC LIMIT 10, 5"
  ["posts"]=>
  array(5) {
    [0]=>
    object(WP_Post)#4767 (24) {
      ["ID"]=>
      int(7121)
      ["post_author"]=>
      string(1) "7"
      ["post_date"]=>
      string(19) "2016-01-11 10:18:36"
      ["post_date_gmt"]=>
      string(19) "2016-01-11 09:18:36"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(209) "Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma."
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(192) "development-of-a-liquid-chromatographytandem-mass-spectrometry-assay-for-the-quantification-of-pm01183-lurbinectedin-a-novel-antineoplastic-agent-in-mouse-rat-dog-cynomolgus-monkey-and-mini-pi"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2017-01-11 10:21:40"
      ["post_modified_gmt"]=>
      string(19) "2017-01-11 09:21:40"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(33) "https://www.pharmamar.com/?p=7121"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
    [1]=>
    object(WP_Post)#3422 (24) {
      ["ID"]=>
      int(7122)
      ["post_author"]=>
      string(1) "7"
      ["post_date"]=>
      string(19) "2016-01-11 10:15:01"
      ["post_date_gmt"]=>
      string(19) "2016-01-11 09:15:01"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(154) "Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 (lurbinectedin) in combiantion with olaparib in patients with advanced solid tumors"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(151) "phase-ibii-study-to-evaluate-the-efficacy-and-tolerability-of-pm01183-lurbinectedin-in-combiantion-with-olaparib-in-patients-with-advanced-solid-tumors"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2017-01-11 10:18:43"
      ["post_modified_gmt"]=>
      string(19) "2017-01-11 09:18:43"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(33) "https://www.pharmamar.com/?p=7122"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
    [2]=>
    object(WP_Post)#3421 (24) {
      ["ID"]=>
      int(7117)
      ["post_author"]=>
      string(1) "7"
      ["post_date"]=>
      string(19) "2016-01-11 10:11:58"
      ["post_date_gmt"]=>
      string(19) "2016-01-11 09:11:58"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(197) "Lurbinectedin (PM01183) administered once (C1) every 3 weeks (q3w) in combiantion with capecitabine (XEL) in patients (pts) with metastatic breast (MBC), colorectal (CRC) or pancreatic (PaC) cancer"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(180) "lurbinectedin-pm01183-administered-once-c1-every-3-weeks-q3w-in-combiantion-with-capecitabine-xel-in-patients-pts-with-metastatic-breast-mbc-colorectal-crc-or-pancreatic-pac-cancer"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2017-01-11 10:14:28"
      ["post_modified_gmt"]=>
      string(19) "2017-01-11 09:14:28"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(33) "https://www.pharmamar.com/?p=7117"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
    [3]=>
    object(WP_Post)#3402 (24) {
      ["ID"]=>
      int(7115)
      ["post_author"]=>
      string(1) "7"
      ["post_date"]=>
      string(19) "2016-01-11 10:10:12"
      ["post_date_gmt"]=>
      string(19) "2016-01-11 09:10:12"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(177) "Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion esults with or withut the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(167) "lurbinectedin-pm01183-plus-paclitaxel-p-recommended-dose-rd-expansion-results-with-or-withut-the-addition-of-bevacizumab-bev-in-patients-pts-with-selected-solid-tumors"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2017-01-11 10:13:26"
      ["post_modified_gmt"]=>
      string(19) "2017-01-11 09:13:26"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(33) "https://www.pharmamar.com/?p=7115"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
    [4]=>
    object(WP_Post)#3403 (24) {
      ["ID"]=>
      int(7109)
      ["post_author"]=>
      string(1) "7"
      ["post_date"]=>
      string(19) "2016-01-11 10:07:51"
      ["post_date_gmt"]=>
      string(19) "2016-01-11 09:07:51"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(102) "PM01183 inactivates the EWS/FLI1 transcription factor by redistributing the protein within the nucleus"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(101) "pm01183-inactivates-the-ewsfli1-transcription-factor-by-redistributing-the-protein-within-the-nucleus"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2017-01-11 10:08:48"
      ["post_modified_gmt"]=>
      string(19) "2017-01-11 09:08:48"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(33) "https://www.pharmamar.com/?p=7109"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
  }
  ["post"]=>
  object(WP_Post)#4767 (24) {
    ["ID"]=>
    int(7121)
    ["post_author"]=>
    string(1) "7"
    ["post_date"]=>
    string(19) "2016-01-11 10:18:36"
    ["post_date_gmt"]=>
    string(19) "2016-01-11 09:18:36"
    ["post_content"]=>
    string(0) ""
    ["post_title"]=>
    string(209) "Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma."
    ["post_excerpt"]=>
    string(0) ""
    ["post_status"]=>
    string(7) "publish"
    ["comment_status"]=>
    string(6) "closed"
    ["ping_status"]=>
    string(6) "closed"
    ["post_password"]=>
    string(0) ""
    ["post_name"]=>
    string(192) "development-of-a-liquid-chromatographytandem-mass-spectrometry-assay-for-the-quantification-of-pm01183-lurbinectedin-a-novel-antineoplastic-agent-in-mouse-rat-dog-cynomolgus-monkey-and-mini-pi"
    ["to_ping"]=>
    string(0) ""
    ["pinged"]=>
    string(0) ""
    ["post_modified"]=>
    string(19) "2017-01-11 10:21:40"
    ["post_modified_gmt"]=>
    string(19) "2017-01-11 09:21:40"
    ["post_content_filtered"]=>
    string(0) ""
    ["post_parent"]=>
    int(0)
    ["guid"]=>
    string(33) "https://www.pharmamar.com/?p=7121"
    ["menu_order"]=>
    int(0)
    ["post_type"]=>
    string(4) "post"
    ["post_mime_type"]=>
    string(0) ""
    ["comment_count"]=>
    string(1) "0"
    ["filter"]=>
    string(3) "raw"
  }
}

Publication: Eur J Cancer

Year: 2016

Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 (lurbinectedin) in combiantion with olaparib in patients with advanced solid tumors

Authors:
Poveda, A.M.; Oaknin, A.; Romero, I.; Guerrero, A.; Fariñas Madrid, L.; Soto, A.; Peris, C.; L. Guerrero, J.A.

Publication: Eur J Cancer

Year: 2016

Lurbinectedin (PM01183) administered once (C1) every 3 weeks (q3w) in combiantion with capecitabine (XEL) in patients (pts) with metastatic breast (MBC), colorectal (CRC) or pancreatic (PaC) cancer

Authors:
Sauri, T.; Awada, A.; Calvo, E.; Moreno, V.; Szyldergemajn, S.; Elez, E.; Barthelemy, P.; Boni, V.; Doger, B.; Fernández Teruel, C.; Soto-Mtos, A.; Tabernero, J.; Aftimos, P.

Publication: Eur J Cancer

Year: 2016

Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion esults with or withut the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors

Authors:
Drilon, A.; Garralda, E.; Stathis, A.; Szyldergemajn, S.; Hyman, D.; Boni, V.; Griguolo, G.; Jimenez Martinez, E.; Makker, V.; Canziani, L.; Fernández Teruel, C.; Soto-Matos, A.; Sessa, C.; Calvo, E.

Publication: AACR American Association for Cancer Research

Year: 2016

PM01183 inactivates the EWS/FLI1 transcription factor by redistributing the protein within the nucleus

Authors:
Harlow, M.; Easton, M.; Guillén Navarro, M.J.; Turner, L.; Hostetter, G.; Galmarini, C.; Aviles, P.; Grohar, P.

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.

Science & Innovation

Our strong commitment to oncology translational research along with our deep understanding of the marine biodiversity of our oceans is placing us at the head of marine biotechnology.

Newsroom

If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom